Keryx Biopharmaceuticals to Present at Two Upcoming Investor Healthcare Conferences

BOSTON, Sept. 01, 2016 -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast management presentations at the following investor conferences:

• Baird’s 2016 Global Healthcare Conference in New York on Thursday, September 8, 2016 at 9:40 a.m. Eastern Time.
• A fireside chat at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 13, 2016 at 12:20 p.m. Eastern Time.

Live audio webcasts of the presentations will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under the “webcasts and presentations” page. Archived versions of the webcasts will be available for at least 15 days following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with headquarters in Boston, is focused on bringing innovative medicines to people with renal disease. In December 2014, the company launched its first FDA-approved medicine, Auryxia^® (ferric citrate) in the United States. In January 2014, ferric citrate was approved for use in Japan, where it is being marketed as Riona^® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric^® (ferric citrate coordination complex). For more information about Keryx, please visit www.keryx.com.

KERYX BIOPHARMACEUTICALS CONTACT:
Lora Pike
Senior Director, Investor Relations
T: 617-466-3511
[email protected]